RxDoctor Payments Data

Eric Rosenwinkel, MD

Clinical Cardiac Electrophysiology · Lansdale, PANPI 1821263799

Payments from drug & device makers

$5,153in general payments, 2019–2025

Across 140 payments — averaging $36.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Boston Scientific$1K
  • Biotronik Inc.$1K
  • Pfizer$283
  • Novartis$195
  • Medtronic$185
  • plus $838 from 15 others

What the payments were for

  • Food & beverage$4,88295%
  • Education$2715%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,153 in reported general payments places this provider in the 15th percentile of 201 clinical cardiac electrophysiology providers in Pennsylvania.

See all clinical cardiac electrophysiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$751,389
Medicare patients
1,178
Services billed
4,352

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban464$472,932
XareltoRivaroxaban94$105,594
EntrestoSacubitril/Valsartan83$99,831
Repatha SureclickEvolocumab29$30,956
FarxigaDapagliflozin Propanediol16$9,149
Dofetilide23$8,839
Metoprolol Succinate424$7,244
Flecainide Acetate138$6,904
Rosuvastatin Calcium363$6,497
Amiodarone Hcl129$5,071
Atorvastatin Calcium253$3,624
Valsartan35$1,981
Ranolazine ErRanolazine15$1,632
Losartan Potassium151$1,594
Carvedilol131$1,487

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$283$472,932464 claims
Johnson & JohnsonXarelto$14$105,59494 claims
NovartisEntresto$195$99,83183 claims
AstraZenecaFarxiga$15$9,14916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 201 clinical cardiac electrophysiology providers in Pennsylvania.

Other clinical cardiac electrophysiology in Lansdale

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →